<DOC>
	<DOCNO>NCT01176266</DOCNO>
	<brief_summary>This clinical trial conduct study hypophosphatasia ( HPP ) , bone disorder cause gene mutation change . These gene mutation cause low level enzyme need harden bone . The purpose study test safety efficacy study drug call asfotase alfa ( human recombinant tissue non-specific alkaline phosphate fusion protein ) see effect patient ≤ 5 year age less HPP .</brief_summary>
	<brief_title>Open-Label Study Asfotase Alfa Infants Children ≤ 5 Years Age With Hypophosphatasia ( HPP )</brief_title>
	<detailed_description>Asfotase alfa formerly refer ENB-0040 Hypophosphatasia ( HPP ) life-threatening , genetic , ultra-rare metabolic disease characterize defective bone mineralization impair phosphate calcium regulation lead progressive damage multiple vital organ , include destruction deformity bone , profound muscle weakness , seizure , impair renal function , respiratory failure . There approve disease-modifying treatment patient disease . There also limit data available natural course disease time , particularly patient juvenile-onset form .</detailed_description>
	<mesh_term>Hypophosphatasia</mesh_term>
	<criteria>Patients must meet follow criterion enrollment study : Parent legal guardian ( ) must provide write informed consent prior study procedure perform must willing comply studyrequired procedure Documented diagnosis HPP indicate : Total serum alkaline phosphatase lower limit normal age Plasma PLP upper limit normal ( unless patient receive pyridoxine seizure ) Radiographic evidence HPP , characterize : Flared fray metaphyses Severe , generalize osteopenia Widened growth plate Areas radiolucency sclerosis Two follow HPPrelated finding : History presence : Nontraumatic postnatal fracture Delayed fracture heal Nephrocalcinosis history elevate serum calcium Functional craniosynostosis Respiratory compromise rachitic chest deformity Vitamin B6 dependent seizures Failure thrive Onset symptom prior 6 month age Chronological age adjust age premature infant bear ≤ 37 week gestation ≤ 5 year Otherwise medically stable opinion Investigator and/or Sponsor Patients low 25 ( OH ) vitamin D level eligible study participation correction level vitamin D supplementation . Exclusion criterion : Patients exclude enrollment study meet follow exclusion criterion : Clinically significant disease precludes study participation , opinion Investigator and/or Sponsor Serum calcium phosphate level normal range Current evidence treatable form rickets Prior treatment bisphosphonates Treatment investigational drug within 1 month prior start asfotase alfa treatment Current enrollment study involve investigational new drug , device treatment HPP ( e.g. , bone marrow transplantation ) Intolerance IP excipients Previous participation study Family relative Investigator NOTE : Historical value PLP may use determine patient eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hypophosphatasia</keyword>
	<keyword>HPP</keyword>
	<keyword>Bone Disease</keyword>
	<keyword>Soft Bones</keyword>
	<keyword>Low Alkaline Phosphatase</keyword>
	<keyword>genetic metabolic disorder</keyword>
	<keyword>alkaline phosphatase</keyword>
	<keyword>tissue-specific alkaline phosphatase ( TNSALP )</keyword>
	<keyword>rickets</keyword>
	<keyword>osteomalacia</keyword>
</DOC>